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Objective: To examine how demographic and pregnancy 
characteristics can affect the risk of recurrent preteI'm 
delivery and the how the effectiveness of progesterone 
treatment for prevention alters these relationships. 
Methods: This was a secondary analysis of a randomized 
trial of 1 7 a-hydroxyprogesterone caproate to prevent recur-
rent preterm delivery in women at risk. Associations of risk 
factors for preterm delivery (less than 37 completed weeks 
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of gestation) were examined separately for the women in 
the 17 a-hydroxyprogesterone caproate (n = 310) and 
placebo (n = 153) groups. 
Results: Univariate analysis found that the number of 
previous preteI'm deliveries and whether the penultimate 
delivery was preteI'm were significant risk factors for pre-
term delivery in both the placebo and progesterone groups. 
High body mass index was protective of preteI'm birth in the 
placebo group. Multivariate analysis found progesterone 
treatment to cancel the risk of more than 1 previous preteI'm 
delivery, but not the risk associated with the penultimate 
pregnancy delivered preteI'm. Obesity was associated with 
lower risk for preterm delivery in the placebo group but not 
in the women treated with progesterone. 
Conclusion: The use of 17 a-hydroxyprogesterone ca-
proate in women with a previous preteI'm delivery reduces 
the overall risk of preterm delivery and changes the epide-
miology of risk factors for recurrent preteI'm delivery. In 
particular, these data suggest that 17a-hydroxyprogester-
one caproate reduces the risk of a history of more than 1 
preteI'm delivery. 
(Obstet Gyneco!2005;706:557-567) 
Level of Evidence: I 
APproximately 10% of all pregnancies in the United States end in pre term birth, and this 10% 
accounts for approximately 70% of the perinatal 
deaths and one half of long-term neurologic morbid-
ity.! Furthermore, the rates of pre term birth have 
been increasing in the United States in the past 
decades.2 Pre term birth is thought to have many 
different causes. Attempts to elucidate these causes by 
examining the epidemiology of pre term birth have 
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identified the association of many risk factors with 
pre term birth, including information about problems 
in previous pregnancies, demographic characteristics, 
and characteristics of the current pregnancy.3.4.5 
Of these various risk factors, 1 of the most 
consistent and powerful is the history of a previous 
pre term delivery. The importance of this risk factor 
has been documented by many studies of various 
populations of pregnant women. 6 - IO Recently, the 
results of 2 randomized trials of treatment using 
17 a-hydroxyprogesterone caproate injections or pro-
gesterone suppositories, respectively, have reported 
efficacy in reducing the rate of recurrent pre term 
delivery in women with this risk factor. These results 
have led to increased interest in women with this 
particular risk characteristic. II •12 However, few studies 
have assessed whether risk factors in addition to a 
previous pre term delivery retain a significant associ-
ation with pre term birth, and no studies have evalu-
ated the potential of progesterone treatment to alter 
risk associations in pregnant women with a previous 
pre term delivery. To examine these questions, we 
performed this secondary analysis of data from a 
randomized trial of 17 a-hydroxyprogesterone ca-
proate to prevent recurrent preterm delivery. 
PATIENTS AND METHODS 
A total of 463 women with at least 1 previous sponta-
neous preterm delivery were enrolled into a random-
ized trial of 17 a-hydroxyprogesterone caproate, using a 
2 to 1 randomization, to prevent recurrent pre term 
birth. Of these, 310 women were treated with the active 
dmg and 153 with placebo injections. The results of this 
trial showed a reduction in the rate of recurrent pre term 
delivery from 54.9% in the placebo group to 36.3% in 
the treatment group. The treatment was equally effective 
in both the African-American and non-African-
American women enrolled. II 
In this article, we evaluated demographic and 
pregnancy characteristics of the study women in the 
treatment and placebo groups of women separately 
for their association with preterm delivery in the 
index (study) pregnancy. The study was approved by 
the institutional review boards at Wake Forest Uni-
versity School of Medicine and at George Washington 
University, the site of our biostatistical center for the 
Maternal-Fetal Medicine Units Network. Variables ex-
amined for associations with preterm delivery in this 
cohort were age, race, parity, pregravid body mass 
index (EMI), education, tobacco and alcohol use, num-
ber of previous preterm deliveries, number of abortions 
or miscarriages, number of previous deliveries, time 
since preterm delivery, previous term delivery, and 
status (term or pre term) of the last delivery. 
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Within each group (17 a-hydroxy progesterone 
caproate and placebo) categorical variables were 
compared with the X2 test and continuous variables 
with the \<Vilcoxon rank-sum test. Next, we deter-
mined whether the association between each charac-
teristic and pre term birth differed between women in 
the progesterone and placebo groups. We did this 
using a logistic regression model that included terms 
for the characteristic, treatment, and an interaction 
between the characteristic and treatment. A signifi-
cant interaction term means that the association be-
tween the characteristic and pre term birth differed 
significantly between women assigned to progester-
one or placebo, ie, that progesterone modified the 
epidemiology of pre term birth. 
A significant interaction was found between pro-
gesterone treatment and 1 risk factor, pregravid EM!. 
As a result, multiple regression models were mn for 
the progesterone and placebo groups of women. 
These separate regression models included variables 
associated with pre term delivery on univariate analy-
sis at the P = .15 level of significance, including more 
than 1 previous pre term delivery, last delivery term or 
preterm, pregravid EMI, and tobacco use. Previous 
term delivery, time since last pre term delivery, and 
the outcome of the last delivery were correlated; 
therefore, only outcome of the last delivery term or 
preterm was included in the final model. Nominal 
2-tailed P values are reported. SAS 8 software (SAS 
Institute, Inc., Cary, NC) was used for the analysis. 
RESULTS 
In this cohort of women, who were at high risk for 
pre term delivery because of a history of a previous 
spontaneous pre term birth, most historical and demo-
graphic risk factors did not have an association with 
pre term delivery in either the 17 a-hydroxyprogester-
one caproate or placebo groups (Tables 1 and 2). 
Among women who received progesterone, the only 
factors significantly associated with preterm delivery 
were having had more than 1 previous pre term 
delivery, shorter time since last pre term delivery, and 
the penultimate delivery having been preterm. 
In the women who did not receive the active 
dmg, the factors that demonstrated an increase in risk 
for pre term delivery were more than 1 previous 
pre term delivery, shorter time since last pre term 
delivery, penultimate delivery preterm, and lower 
pregravid EM!. 
Examination of interactions and treatment found 
a highly significant association with pregravid EMI 
and 17 a-hydroxyprogesterone caproate treatment, 
P < .001. When variables associated with pre term 
birth on univariate analysis (P < .15) were examined 
using logistic regression analysis, the associations of 
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Table 1. Preterm Delivery in the Current Pregnancy Based on Historical Risk Factors, Examined 
Separately Among Women Receiving Progesterone or Placebo 
Progesterone Group 
(N = 310) 
Placebo Group 
(N = 153) 
Risk Factors Pretenn p Pretenn p 
No. of previous pretenn deliveries 
1 
>1 





Previous term delivery 
Yes 
No 
Outcome of penultimate pregllancy 
Tenn 
Pre term 
No. of previous term and preterm deliveries 
Pre term, index pregnancy 
Tenn 
Time since last pretenn delivery (y) 
Pre term, index pregnancy 
Tenn 















these risk factors with pre term birth were altered, as 
shown in the final models in Tables 3 and 4. The 
associations of pregravid EMI with pre term delivery 
differ strikingly between the 2 study groups. In the 
placebo group, high pregravid EMI had a highly 
significant negative (protective) association with pre-
term delivery, and low pregravid EMI was in the 
direction of a positive association of increased risk, 
(odds ratio 3.9, P = .098). In the 17 a-hydroxyproges-
terone caproate group, neither low nor high pregravid 
EMI was associated with an altered risk of preterm 
delivery. 
\-Ye found an association between pre term deli v-
ery in the pregnancy immediately preceding the 
current gestation ("penultimate pregnancy") and pre-
term delivery in the current pregnancy. A pre term 
delivery in the penultimate pregnancy was signifi-
cantly associated with preterm delivery in the 17 a-
hydroxyprogesterone caproate group (P = .005), and 
in the placebo group (P = .043). Tobacco use was not 
found to be associated with pre term delivery in either 
multivariate model. More than 1 preterm delivery 
retains a strong association in the placebo group, with 
odds ratio of 3.38 (P = .009), but no significant 
association in the 17 a-hydroxyprogesterone caproate 
group (P = .153) 
DISCUSSION 
This analysis provides useful information to clini-
cians. \-Yomen recruited to the trial and randomly 




























assigned to placebo were at high risk for pre term 
delivery due to their history of a previous spontane-
ous preterm delivery. This risk was modified by 
several maternal characteristics. It was greatly in-
creased if they had had more than 1 preterm delivery, 
was increased if the last delivery was pre term, and 
was decreased if the woman's pregravid body mass 
index was high (obese). 
Treatment with 17 a-hydroxyprogesterone ca-
proate not only decreased the overall risk of preterm 
delivery, but the increased risk of pre term birth 
related to a history of more than 1 previous pre term 
delivery was no longer apparent with progesterone 
treatment. A significantly increased risk for pre term 
delivery remained in this group of treated subjects if 
the penultimate pregnancy was delivered pre term. 
Some of the results of this study should be 
interpreted with caution, because the analysis lacked 
the power to evaluate the significance of some of these 
associations. This is particularly true for the placebo 
group of patients. For example, low EMI had a high 
odds ratio for pre term delivery in the placebo group, 
but there were too few subjects (20) with this charac-
teristic to reach statistical significance. Likewise, eval-
uation of characteristics such as race and age may 
have been limited by the sample size. 
This study confirms that the presence of several 
factors add significant increased risk for recurrent 
pre term delivery in women with a history of a previ-
ous preterm delivery. Previous investigators have 
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Table 2. Preterm Delivery in the Current 
Pregnancy Based on Demographic 
Characteristics, Examined Separately 
Among Women Receiving Progesterone 
or Placebo 
Progesterone 
Group Placebo Group 
(N = 310) (N = 153) 
Risk Factors Pretenn P Pretenn P 
Maternal age (y) 
< 18 33.3 .967 62.5 .917 
19-36 36.4 54.7 
>36 37.5 50.0 
Parity 
::=.2 34.8 .449 59.1 .128 
1 39.2 45.8 
Maternal race 
African American 35.4 .689 52.2 .426 
N on-African American 37.6 58.7 
Pregravid body mass 
index 
< 20 37.5 .883 80.0 < .001 
20-29 34.8 62.0 
> 29 37.6 24.3 
Maternal education (y) 
:<:: 12 35.9 .811 53.4 .592 
> 12 37.4 58.0 
Tobacco use 
Yes 32.9 .498 70.0 .064 
No 37.3 51.2 
Alcohol use 
Yes 33.3 .739 50.0 .755 
No 36.6 55.2 
Values are percentages. 
Table 3. Logistic Regression Analysis of Risk 
Factors for Preterm Birth in Women 




Risk Factors Ratio Interval P 
> 1 previous pretenn 1.54 0.85-2.79 . 153 
Last delivery preterm 2.81 1.36-5.82 .005 
Body mass index 
< 20 1.29 0.58-2.88 .535 
Body mass index 
> 29 1.75 0.94-3.24 .077 
Tobacco use 0.72 0.35-1.45 .354 
reported a high rate of recurrent preterm delivery, 
with rates of pre term delivery from 15% to 62%, 
depending on the population studied and on the 
number of prior pre term deliveries. In the population 
of women entered into this trial, the rate of pre term 
delivery at less than 35 weeks of gestation was very 
similar to the report of Owen et al13 of a group of 
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Table 4. Logistic Regression Analysis of Risk 
Factors for Preterm Birth in Women 
Treated With Placebo 
95% 
Odds Confidence 
Risk Factors Ratio Interval 
> 1 previous pre term 3.38 1.36-8.40 
Last delivery pre term 3.07 1.03-9.13 
Body mass index 
< 20 3.92 0.78-19.79 





> 29 0.14 0.05-0.38 < .001 
Tobacco use 1.48 0.49-4.54 .49 
women with a prior pre term delivery in the Maternal-
Fetal Medicine Units Network. 
Previous investigators have identified several risk 
factors for recurrent pre term delivery. Adams found 
that African-American women had higher rates of 
recurrent pre term birth than white women, and that 
additional significant risk factors were young age and 
short interpregnancy interval. 7 Other investigators 
have not found that race modifies the risk for recur-
rent pre term delivery. Race may not have indicated a 
significant risk for recurrent pre term deli very for 
several reasons. The majority of our subjects were 
African American, the sample size was relatively 
small, and a previous pre term delivery may have 
produced a greater increase in risk for recurrent 
pre term delivery for white women. 
Several investigators have examined risk factors 
for recurrent pre term birth in the Maternal-Fetal 
Medicine Units Network Preterm Prediction Study. 
Mercer et aP identified low BMI, high Bishop score, 
and history of vaginal bleeding as significant risk 
factors, whereas lams et als found that both a short 
cervix, measured by transvaginal ultrasound, and a 
positive fetal fibronectin test significantly predicted 
recurrent pre term delivery. Information from these 
last tests was not available in the current study . 
The modification of the associations between 
body mass index and pre term delivery by progester-
one treatment is striking. Women with a high BMI 
had a lower risk of recurrent pre term delivery; how-
ever, this protective effect of obesity was not found in 
the 17 a-hydroxyprogesterone caproate-treated women. 
These results may represent a dilutional effect of the 
dose used in larger women. A recent report by Holt et 
a}l4 found that oral contraceptives were less effective 
in preventing pregnancy in obese women. The results 
may also be attributed to impaired absorption of 
dmgs administered by injection to obese individuals. 
A computer search was performed of PubMed 
using the terms "pre term birth" and "progesterone," 
yielding 150 published papers from 1965 to the 
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present. This study is the first to examine how treat-
ment with progesterone influences the effect of other 
risk factors for recurrent preterrn delivery. The mod-
ification of risk factors by progesterone treatment may 
provide insight into the mechanisms of action of 
progesterone to prevent preterrn birth. It is likely that 
pre term birth has multiple possible causes. Perhaps 
recurrent pre term deliveries are related to a problem 
for which progesterone treatment is particularly effi-
cacious. This analysis also provides reassuring infor-
mation for women with more than 1 previous pre term 
delivery. Our findings suggest that progesterone treat-
ment remains effective in the prevention of pre term 
delivery in this population at very high risk for 
recurrent pre term delivery. 
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sity of Texas at San Antonio: O. Langer, S. Nicholson; 
University of Texas at Houston: M. C. Day, L. Gilstrap; 
University of Texas Southwestern Medical Center: J. Mc-
Campbell, G. Wendel; Drexel University: M. DiVito, J. 
Tolosa; University of Utah: M. Belfort, E. Taggart; Wake 
Forest University: E. Mueller-Heubach, M. Swain; Wayne 
State University: G. Norman, Y. Sorokin. 
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